ReviewPharmaceutics2023
Recent Preclinical and Clinical Progress in Liposomal Doxorubicin.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed.
- Liposomal doxorubicin plus nab-paclitaxel with/without chemoradiotherapy in head and neck adenoid cystic carcinoma: single-arm phase II study.Signal transduction and targeted therapy · 2026Trial
- Cryopreservation technology for improving the stability of liposomes and its precise drug monitoring in clinical drug research.Drug delivery · 2026Article
- Unlocking the brain: Biodistribution insights into tween 80 nanoliposomes in healthy brains.International journal of pharmaceutics: X · 2026Article
- Doxorubicin-driven reconfiguration of BSA-cushioned DPPC liposomes an integrated molecular-dynamics and AFM roadmap for next-generation drug-delivery platforms.Nanoscale advances · 2026Article
- Lactococcal Extracellular Vesicles as In Situ Vaccine Activators in Combination with Doxorubicin for Cancer Therapy.Pharmaceutics · 2026Article
- Emerging paradigms in nanostructured targeted drug delivery systems.Discover nano · 2026Review
- Safety and Treatment Efficacy of Systemic, Locoregional, and Nanoparticle Encapsulated Anthracycline Chemotherapy: Insights Into Cardiotoxicity.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Artificial intelligence-assisted design and optimization of stimuli-responsive nanocarriers for smart drug delivery.Materials today. Bio · 2026Review
- Nanoparticles synthesis, properties and promising devices for drug delivery systems: a review.Discover nano · 2026Review
- Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity.Nanoscale advances · 2026Review
- Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Transforming tumor microenvironments: nanotechnology and gene therapy in cellular signaling and epigenetic insight into chemo-resistance.Journal of experimental & clinical cancer research : CR · 2026Review
- Nanoparticles for Doxorubicin Delivery: Advances in Carrier Design and Synergistic Cancer Therapy.Topics in current chemistry (Cham) · 2026Review
- Harnessing Folate-Mediated PSMA Targeting for Precision Therapy: An Intelligent Liposomal Nanoplatform Against Prostate Cancer.Pharmaceutics · 2026Article
- Exosomes displaying native EGF enhance doxorubicin's therapeutic efficacy and reduce cardiotoxicity.Journal of nanobiotechnology · 2026Article
- Nanotechnology in Cutaneous Oncology: The Role of Liposomes in Targeted Melanoma Therapy.Molecules (Basel, Switzerland) · 2026Review
- Nanoparticles in HIV treatment for improved drug delivery, clinical translation, and future direction.Discover nano · 2026Review
- Nanotechnology-Driven Cancer Therapies for Precision Oncology: Advances and Clinical Outlook.International journal of nanomedicine · 2026Review
- Design Evolution of Curcumin-Loaded Nanostructured Lipid Carriers: Formulation Strategies, Functional Modifications, and Mechanistic-Translational Perspectives.International journal of nanomedicine · 2026Review
- Next Generation DNA Damage Response Inhibitors: Harnessing Nanocarriers and Tumor Microenvironment for Precision Cancer Therapy.Oncology research · 2026Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin (DOX) is a potent anti-cancer agent that has garnered great interest in research due to its high efficacy despite dose-limiting toxicities. Several strategies have been exploited to enhance the efficacy and safety profile of DOX. Liposomes are the most established approach. Despite the improvement in safety properties of liposomal encapsulated DOX (in Doxil and Myocet), the efficacy is not superior to conventional DOX. Functionalized (targeted) liposomes present a more effective system to deliver DOX to the tumor. Moreover, encapsulation of DOX in pH-sensitive liposomes (PSLs) or thermo-sensitive liposomes (TSLs) combined with local heating has improved DOX accumulation in the tumor. Lyso-thermosensitive liposomal DOX (LTLD), MM-302, and C225-immunoliposomal(IL)-DOX have reached clinical trials. Further functionalized PEGylated liposomal DOX (PLD), TSLs, and PSLs have been developed and evaluated in preclinical models. Most of these formulations improved the anti-tumor activity compared to the currently available liposomal DOX. However, the fast clearance, the optimization of ligand density, stability, and release rate need more investigations. Therefore, we reviewed the latest approaches applied to deliver DOX more efficiently to the tumor, preserving the benefits obtained from FDA-approved liposomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.